Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429300 | 0.91 | F10 (0.51) | F10ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3425891 | 0.90 | F10 (0.41) | F10ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3428575 | 0.87 | F10 (0.48) | F10 | |
| SCHEMBL3428572 | 0.86 | F10 (0.47) | F10ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3427642 | 0.85 | F10 (0.49) | F10ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3421749 | 0.83 | F10 (0.48) | F10MEN1KMT2AMAPTHTT | |
| SCHEMBL3777662 | 0.83 | F10 (0.48) | F10MEN1KMT2AMAPTHTT | |
| SCHEMBL3771943 | 0.83 | F10 (0.48) | F10MEN1KMT2AMAPTHTT | |
| SCHEMBL3424315 | 0.83 | F10 (0.45) | F10ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3429455 | 0.82 | F10 (0.40) | F10ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293300-A1 | New substituted thiophene carboxamides, process for their preparation and their use as medicaments | OTC, TPMT, ABCG2 | F10 1901/4885ALDH1A1 1734/4885MEN1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.